TNGX
NASDAQTango Therapeutics
$31.56
+0.63 (+2.04%)
2026-06-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$3.20B
P/E Ratio
N/A
52W Low
52W High
$6.69
$32.79
Volume
7.1M
Analyst Rating
Hold
Target: $22
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $14
Avg: $22
High: $32
About Tango Therapeutics
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...
Employees
137
Website
tangotx.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $62.4M | -178.4% | -$101.6M | -$137.8M |
| 2024 | $42.1M | -346.1% | -$130.3M | -$130.7M |
| 2023 | $36.5M | -312.6% | -$101.7M | -$116.5M |
| 2022 | $24.9M | -446.8% | -$108.2M | -$101.4M |
| 2021 | $37.0M | -157.1% | -$58.2M | -$57.7M |
| 2026 Q1 | N/A | N/A% | -$45.5M | -$44.4M |
| 2025 Q4 | N/A | N/A% | -$38.7M | -$29.5M |
| 2025 Q3 | $53.8M | 26.2% | $15.9M | -$30.8M |
| 2025 Q2 | $3.2M | -1287.9% | -$38.9M | -$35.9M |
| 2025 Q1 | $5.4M | -788.8% | -$39.9M | -$41.6M |
| 2024 Q4 | $4.1M | -993.7% | -$37.7M | -$36.5M |
| 2024 Q3 | $11.6M | -283.3% | -$29.2M | -$33.3M |
| 2024 Q2 | $19.9M | -148.7% | -$25.6M | -$23.3M |